Zhejiang Huahai Pharmaceutical announced that the abbreviated new drug application (ANDA) for the saxagliptin metformin tablets submitted to the USA FDA has received temporary approval. This pharmaceutical is mainly used for the treatment of type 2 diabetes and was developed by MSD SUB MERCK, first launched in the USA in March 2007.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
华海药业:西格列汀二甲双胍片获美国FDA暂时批准文号
Zhejiang Huahai Pharmaceutical: The saxagliptin metformin tablets have received temporary approval from the USA FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 243
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report